Get the Stockscreener App
0.195
4.65%
-0.0095
After Hours:
.18
-0.015
-7.69%
Kintara Therapeutics Inc stock is traded at $0.195, with a volume of 1.01M.
It is down -4.65% in the last 24 hours and up +4.45% over the past month.
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.
See More
Previous Close:
$0.2045
Open:
$0.194
24h Volume:
1.01M
Relative Volume:
0.27
Market Cap:
$10.53M
Revenue:
-
Net Income/Loss:
$-10.58M
P/E Ratio:
-0.0205
EPS:
-9.49
Net Cash Flow:
$-6.79M
1W Performance:
+19.56%
1M Performance:
+4.45%
6M Performance:
+87.50%
1Y Performance:
-95.17%
1-Day Range:
$0.1881
$0.1975
1-Week Range:
$0.16
$0.218
52-Week Range:
$0.081
$4.5861
Kintara Therapeutics Inc Stock (KTRA) Company Profile
Name
Kintara Therapeutics Inc
Sector
Industry
Phone
(858) 350-4364
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 150, SAN DIEGO
Kintara Therapeutics Inc Stock (KTRA) Latest News
Kintara Therapeutics modifies merger terms with TuHURA Biosciences By Investing.com - Investing.com Canada
Kintara Therapeutics Inc Inc. (KTRA) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Kintara Therapeutics modifies merger terms with TuHURA Biosciences - Investing.com India
Kintara Therapeutics modifies merger terms with TuHURA Biosciences - Investing.com
Kintara Therapeutics modifies merger terms with TuHURA Biosciences By Investing.com - Investing.com Australia
Kintara Therapeutics modifies merger terms with TuHURA Biosciences By Investing.com - Investing.com UK
Kintara Therapeutics Inc (KTRA) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Kinross Gold (NYSE:KGC) Lowered to Buy at StockNews.com - Defense World
Kintara Therapeutics announces special stockholder meeting - Investing.com
Viking Therapeutics Unusual Options Activity For September 24 - Benzinga
Results from Kintara Therapeutics Inc (KTRA) show risk - US Post News
Kintara Urges Shareholder Votes for TuHURA Biosciences Merger - TipRanks
Viking Therapeutics (NASDAQ:VKTX) Rating Increased to Sell at StockNews.com - MarketBeat
Kintara Therapeutics (NASDAQ:KTRA) Shares Down 6.3% - Defense World
Kaival Brands Shares More Than Double on Delta Corp Holdings Merger - MarketWatch
Viking Therapeutics (NASDAQ:VKTX) Trading Down 3% After Insider Selling - MarketBeat
Knight-Swift Transportation Holdings Inc. (NYSE:KNX) is Interval Partners LP's 10th Largest Position - MarketBeat
Balance Sheet Insights: Kintara Therapeutics Inc (KTRA)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Kintara delays special meeting vote on key proposals By Investing.com - Investing.com Canada
Viking therapeutics CEO sells over $15m in company stock By Investing.com - Investing.com Australia
Viking therapeutics director sells shares worth over $715,000 - Investing.com
Viking therapeutics director sells shares worth over $715,000 By Investing.com - Investing.com UK
Kintara delays special meeting vote on key proposals - Investing.com
Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024 - PR Newswire
Kintara delays special meeting vote on key proposals By Investing.com - Investing.com Australia
Inspire Investing LLC Has $2.33 Million Stock Holdings in Kyndryl Holdings, Inc. (NYSE:KD) - Defense World
Kintara Announces Special Meeting for Proposed TuHURA Merger - TipRanks
Viking Therapeutics Inc [VKTX] Shares Rise 2.40 % on Wednesday - Knox Daily
StockNews.com Upgrades Kinross Gold (NYSE:KGC) to Strong-Buy - Defense World
A Deep Dive into Kintara Therapeutics Inc (KTRA) Stock Performance - The InvestChronicle
Kintara Therapeutics Seeks Approval for Key Merger with TuHURA Biosciences - TipRanks
Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences - PR Newswire
Bank of New York Mellon Corp Increases Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - Defense World
Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger… - Informazione.it
Viking Therapeutics Inc (VKTX) gets rating Initiated from JP Morgan - Knox Daily
What the Options Market Tells Us About Viking Therapeutics - Benzinga
Kinross Gold Co. (NYSE:KGC) Shares Sold by DekaBank Deutsche Girozentrale - Defense World
Ratio Revelations: Kintara Therapeutics Inc (KTRA)’s Financial Metrics in the Spotlight - The Dwinnex
There is no way Kintara Therapeutics Inc (KTRA) can keep these numbers up - SETE News
Total Clarity Wealth Management Inc. Has $336,000 Stock Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Knight-Swift Transportation Holdings Inc [KNX] Director makes an insider sale of 2,000 shares worth $0.1 million. - Knox Daily
Kintara Therapeutics Inc (KTRA)’s stock price in review: A technical analysis - US Post News
Ashton Thomas Private Wealth LLC Purchases Shares of 5,361 Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - Defense World
Kintara advances merger, seeks REM-001 study progress - Investing.com India
Get in on Kintara Therapeutics Inc’s (KTRA) buy-in window today! - SETE News
Kintara advances merger, seeks REM-001 study progress - Investing.com
Kintara Therapeutics Advances with TuHURA Merger and Trials - TipRanks
Kintara provides update on REM-001 clinical study - TipRanks
Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study - PR Newswire
Kintara urges stockholder vote for TuHURA merger - Investing.com
Kintara urges stockholder vote for TuHURA merger By Investing.com - Investing.com Canada
Kintara Therapeutics Inc Stock (KTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):